Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Trial Details

NCT ID
NCT06584032
Phase
PHASE3
Sponsor
Hutchmed
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • fruquintinib
  • sintilimab
  • paclitaxel
  • doxorubicin
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Have fully understood and voluntarily signed the informed consent form
  • Age 18 to 75 years (inclusive) ; Body mass index (BMI) ≥ 18.5kg/m\^2;
  • Histologically or cytologically confirmed advanced or recurrent endometrial cancer with measurable lesions
  • Patients who previously failed first-line systemic platinum-based therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →